☆ 4.7 Article

Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment

PHYTOMEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies

Santhosshi Narayanan et al.

Summary: The systematic review focused on clinical studies of mushroom supplements in cancer care conducted in the past 10 years. The studies showed that mushroom preparations can have positive effects in reducing chemotherapy toxicity, improving quality of life, promoting immune response, and possibly improving clinical outcomes. However, the current evidence is inconclusive to recommend the routine use of mushrooms for cancer patients, and more trials are needed to explore their use during and after cancer treatment.

CURRENT ONCOLOGY REPORTS (2023)

Add to Collection

Review Immunology

Immunoregulatory effects of Huaier (Trametes robiniophila Murr) and relevant clinical applications

Hongrong Long et al.

Summary: Huaier, a medicinal fungus in traditional Chinese medicine, has a long history of clinical application and remarkable anticancer activities. Recent studies have uncovered its immunomodulatory effects, which have shown benefits in various immune-related diseases. This review comprehensively summarizes the active components of Huaier, its regulatory activities on the immune system, its clinical applications, as well as toxicologic evidence. Huaier has broad-spectrum regulatory activities on various components of the immune system, and its modulatory activities promote restoration to normal physiological status. With excellent efficacy and minimal side effects, Huaier holds promise for treating immune-related disorders.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

Yudong Su et al.

Summary: This study dynamically evaluated the effect of anlotinib, a multitarget antiangiogenic tyrosine kinase inhibitor, on the tumor microenvironment (TME). The results showed that anlotinib facilitated tumor vessel normalization, reprogrammed the immunosuppressive TME into an immunostimulatory TME, and significantly inhibited tumor growth. Combination treatment with anlotinib and a PD-1 checkpoint inhibitor counteracted immunosuppression and induced neuroblastoma regression. These findings have important clinical value and provide guidance for the testing of related drugs in neuroblastoma and other cancers.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Meeting Abstract Oncology

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Ghassan K. Abou-Alfa et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model

Yuhua Wei et al.

Summary: This study demonstrates that the combination of FAK inhibitor VS4718 and anti-PD1 therapy has a better effect in treating HCC compared to monotherapy. It reduces the number of Tregs and macrophages while increasing the number of CD8(+) T cells. Additionally, the FAK inhibitor promotes the expression of PD-L1 in HCC.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Oncology

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Mengling Wu et al.

Summary: PD-1/PD-L1 immune checkpoints inhibit the anticancer effect of T cells in the tumor microenvironment, and downregulation or upregulation of PD-L1 expression can improve the efficacy of anti-PD-1/PD-L1 treatment. Overcoming the current limitations of this treatment can expand its anticancer applications and improve patient response rates and survival time.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Pathology

PD-L1 immunostaining: what pathologists need to know

Mohammed Akhtar et al.

Summary: Immune checkpoint therapy relies on inhibitors of PD-L1 and PD-1 proteins to reactivate the immune system to fight cancer. This therapy requires demonstration of PD-L1 activation on tumor cells through immunohistochemical staining.

DIAGNOSTIC PATHOLOGY (2021)

Add to Collection

Article Plant Sciences

Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study

Zhen Wang et al.

Summary: Clinical trials have shown that Huaier granules in combination with thermal ablation can benefit HCC patients by improving overall survival, progression-free survival, and reducing extrahepatic metastatic rates. Younger patients with single tumors and tumors smaller than 3 cm may experience better outcomes with the integrated treatment approach.

JOURNAL OF ETHNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Pathology

Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma

Leonardo Franz et al.

Summary: The study aimed to investigate the correlation between angiogenesis, PD-L1 expression, and immune microenvironment in LSCC and found that CD31-assessed MVD and TILs had independent prognostic value. There was a significant negative correlation between CD31-assessed MVD values and PD-L1 CPS, while PD-L1 CPS and TILs count rate were positively correlated. The integrated interpretation of these markers may have clinical relevance for a synergistic effect of combining anti-angiogenic drugs with PD-1/PD-L1 checkpoint inhibitors in advanced LSCC.

PATHOLOGY (2021)

Add to Collection

Article Oncology

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

Masahiro Morita et al.

Summary: This study identified prognostic factors for anti-PD-1 antibody treatment in advanced HCC based on molecular and immunological features. Factors associated with better response included low alpha-fetoprotein levels, negative beta-catenin/GS staining, high CPS of PD-L1, and increased CD8(+) cell infiltration. Negative staining of beta-catenin/GS, CPS of PD-L1 >= 1, and high CD8(+) TILs were significantly associated with longer survival. These findings suggest that the combined score of Wnt/beta-catenin activation, CPS of PD-L1, and CD8(+) TILs can predict the response to ICI in HCC cases.

LIVER CANCER (2021)

Add to Collection

Article Oncology

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

Huiying Han et al.

CANCER CELL (2019)

Add to Collection

Article Gastroenterology & Hepatology

Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial

Qian Chen et al.

GUT (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma

Yuquan Tao et al.

JOURNAL OF CANCER (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Expansion of the Gene Ontology knowledgebase and resources

S. Carbon et al.

NUCLEIC ACIDS RESEARCH (2017)

Add to Collection

Meeting Abstract Oncology

Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

Sha Zhao et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Article Oncology

Huaier Restrains Proliferative and Migratory Potential of Hepatocellular Carcinoma Cells Partially Through Decreased Yes-Associated Protein 1

Liang Shan et al.

JOURNAL OF CANCER (2017)

Add to Collection

Review Oncology

Combination immunotherapy: a road map

Patrick A. Ott et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

Add to Collection

Article Plant Sciences

Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling

Zhongdong Hu et al.

JOURNAL OF ETHNOPHARMACOLOGY (2016)

Add to Collection

Article Oncology

A Huaier polysaccharide reduced metastasis of human hepatocellular carcinoma SMMC-7721 cells via modulating AUF-1 signaling pathway

Cong Li et al.

TUMOR BIOLOGY (2015)

Add to Collection

Article Oncology

A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice

Yanmei Zou et al.

TUMOR BIOLOGY (2015)

Add to Collection

Article Oncology

A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis

Cong Li et al.

TUMOR BIOLOGY (2015)

Add to Collection

Article Chemistry, Applied

A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects

Yi Sun et al.

CARBOHYDRATE POLYMERS (2013)

Add to Collection

Article Oncology

Anti-angiogenic and antitumor activities of Huaier aqueous extract

Xiaolong Wang et al.

ONCOLOGY REPORTS (2012)

Add to Collection

Review Oncology

The immune contexture in human tumours: impact on clinical outcome

Wolf Herman Fridman et al.

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibitory effect of extract of fungi of Huaier on hepatocellular carcinoma cells

Jianzhuang Ren et al.

JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.